Clinical trials: sponsored by Neurocrine Biosciences
Brain and Central Nervous System Tumors
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: NBI-3001 may be able to locate cancer cells and stop them from growing. This may be an effective treatment for glioblastoma multiforme.
- Trial name
- NCT00014677
- Testing
- interleukin-4 PE38KDEL cytotoxin, conventional surgery
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Breast Cancer, Kidney Cancer
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00039052
- Testing
- interleukin-4 PE38KDEL cytotoxin
- Where
- 2 sites in United States
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective…
- Trial name
- NCT01267188
- Testing
- NBI-98854
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Neurocrine Biosciences
Type 1 Diabetes Mellitus
A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus
This was a study designed to evaluate the efficacy of multiple doses of an investigational drug, NBI-6024, in adult (18 to 35 years of age) and adolescent (10 to 17 years of age) patients with new onset type 1 diabetes mellitus…
- Trial name
- NCT00873561
- Testing
- NBI-6024
- Where
- 21 sites in Canada, Czechia and 6 more
- Volunteers
- 188 people
- Sponsor
- Neurocrine Biosciences
Multiple Sclerosis
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects.
- Trial name
- NCT00079495
- Testing
- NBI-5788
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Insomnia, Depression
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
- Trial name
- NCT00232167
- Testing
- Indiplon, Sertraline
- Volunteers
- 380 people
- Sponsor
- Neurocrine Biosciences